The Odylia Collective has merged with Comend

Last year, we introduced The Odylia Collective—a centralized marketplace designed to make essential resources more accessible for patient groups and rare disease researchers.

We are proud to share we have officially partnered with Comend to unite our efforts under their innovative new platform. This collaboration is built to empower patient groups, streamline navigation of the drug development process, and spark more impactful partnerships across the rare disease ecosystem.

Odylia has partnered with Comend (read the press release here) to merge efforts and support the launch of the innovative platform, designed to make translational research—early-stage work with real-world impact—accessible to everyone, not just experts.

We’re thrilled by how far this project has come—far exceeding our expectations in under a year. The enthusiasm and support from patient groups and the rare disease community has played a key role in moving this initiative forward.